Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of
July 11 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International
Develops Adjuvant Technology to Enhance Prostate Cancer
Suppressing Properties of NanoPSA
Company Reports Synergistic
Activation of Anti-Cancer Protein NRF2 By Proprietary Combination
Approach
OCEANSIDE, CA -- July
11, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today the
further development of a mustard seed extract containing the enzyme
myrosinase for hydrolyzation of glucoraphanin into
sulforaphane.
Mustard seeds and
mustard products are consumed worldwide with a wide variety of
mustard seeds and plants. Among several compounds found in mustard
seeds is the enzyme myrosinase, responsible for the
hydrolysis of glucoraphanin into sulforaphane, our target
compound.
This companion
extract was simultaneously developed alongside
NanoPSA, our proprietary
glucoraphanin product. Although we know the gut flora is capable of
myrosinase-like activity in the
absence of myrosinase, we want to be sure to convert as much of the
glucoraphanin into sulforaphane as we can.
Sulforaphane appears
to act on the prototypical anti-inflammatory mechanism of
inhibiting NF-kB translocation, a mechanism which disrupts
inflammatory signals to the nucleus [1]. Anti-inflammatory
effects of Sulforaphane are mediated by preventing NF-kB from
translocating to the nucleus, which disrupts pro-inflammatory
signals from the cytosol and serum from acting in the
nucleus.
For example, in
rheumatoid arthritis, characterized by inflammation and rapidly
proliferating synoviocytes, is
commonly
seen as a treatment target [2]. Sulforaphane appears to be able to,
in vitro in cultured synoviocytes, suppress TNF-a induced
inflammation and proliferation when pre-incubated (secondary to
activating Nrf2) and induce apoptosis in cultures already
stimulated with TNF-a [3].
"The
cancer-suppressing properties of sulforaphane are well known.
Through combination with pterostilbene, we believe that NanoMyros
(pronounced nanomuhross) is a non-toxic
means of concurrently stimulating anticancer immunity while
directly suppressing the antimetastatic and antiangiogenic
activities of sulforaphane" said Timothy Dixon, President, and CEO
of Therapeutic Solutions International. "Recent data suggests that
classical drug treatments such as chemotherapy induce immune system
activation. We believe that NanoMyros together with NanoPSA
are potent agents which can magnify cancer-killing activity of
various existing therapies, as well as
be used as a monotherapy in certain circumstances."
[1] https://www.ncbi.nlm.nih.gov/pubmed/11410599
[2] https://www.ncbi.nlm.nih.gov/pubmed/20193003
[3] https://www.ncbi.nlm.nih.gov/pubmed/23072510
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024